NeoGenomics rises as Medicare covers new cancer blood test
16/03/2026 11:23
** Shares of cancer testing firm NeoGenomics NEO.O rise 1.1% to $7.97 premarket ** Co says Medicare will now cover its PanTracer LBx blood test ** Test looks for genetic changes linked to cancer, helping doctors pick treatments and clinical trials ** PanTracer LBx checks more than 500 genes and delivers results in about seven days - NEO ** Co says test is run at NeoGenomics’ California lab; co operates labs across the U.S. and the UK ** Shares down ~29% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on NeoGenomics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
NeoGenomics rises after BTIG upgrades to 'buy'
Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
Brief: Neogenomics Receives Medicare Coverage For Radar St For Immunotherapy Treatment Response Monitoring